Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

311
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
311
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

372
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
372

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global surveillance reveals progressive erosion of benzylpenicillin susceptibility in Streptococcus suis.

The Journal of infection·2026
Same author

Ripk2 promotes CD8<sup>+</sup> T cell inactivation and hepatocellular carcinoma progression through Myb/Cxcl9 and Pax5/Adpgk signaling pathways.

Cell death & disease·2026
Same author

Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli.

The Journal of antimicrobial chemotherapy·2026
Same author

SPCS2 serves as a critical host factor for JEV replication by regulating viral protein stability and virion assembly.

Microbiology spectrum·2026
Same author

Display-based augmented reality navigation for CT-Guided thoracoabdominal punctures: phantom study of accuracy and workflow efficiency.

Biomedical physics & engineering express·2026
Same author

Phosphoproteomics elucidates the functional impact of the PTPN11 p.Asn308Ser variant in a Noonan syndrome pedigree.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2026

Related Experiment Video

Updated: Dec 6, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.4K

Effect of superselective prostatic artery embolization on benign prostatic hyperplasia.

Yi Tang1,2, Jian-Hui Zhang1, Yao-Bin Zhu3

  • 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.

Abdominal Radiology (New York)
|October 7, 2020
PubMed
Summary

Superselective prostatic artery embolization (PAE) is a safe and effective treatment for benign prostatic hyperplasia (BPH). Bilateral PAE demonstrated superior efficacy compared to unilateral PAE in improving patient symptoms and outcomes.

Keywords:
Benign prostatic hyperplasiaInterventional embolizationProstatic arterial embolization

More Related Videos

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.3K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.5K

Related Experiment Videos

Last Updated: Dec 6, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.4K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.3K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.5K

Area of Science:

  • Interventional Radiology
  • Urology
  • Medical Devices

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition affecting aging men.
  • Current treatments for BPH include medication and surgery, but these may have limitations or side effects.
  • Superselective prostatic artery embolization (PAE) offers a minimally invasive alternative for BPH management.

Purpose of the Study:

  • To evaluate the safety and efficacy of superselective PAE in patients with BPH.
  • To compare the outcomes of bilateral versus unilateral PAE.

Main Methods:

  • A cohort of 65 BPH patients unsuitable for or refusing surgery underwent PAE.
  • Procedures included bilateral or unilateral embolization.
  • Patients were followed for 6 months, assessing complications, clinical symptoms, prostate-specific antigen (PSA), and prostatic volume (PV).

Main Results:

  • Successful PAE was achieved in 89.23% of patients (58/65).
  • Clinical efficacy reached 94.83% at 6 months, with significant improvements in PV, IPSS, QoL, and maximum flow rate (P < 0.05).
  • Bilateral PAE showed better efficacy than unilateral PAE, with no serious complications reported.

Conclusions:

  • Superselective PAE is a safe and effective treatment option for BPH.
  • Bilateral PAE is more effective than unilateral PAE for improving BPH symptoms and outcomes.